Icon Wealth Advisors LLC Acquires 75,569 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Icon Wealth Advisors LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 18,342.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 75,981 shares of the biopharmaceutical company's stock after purchasing an additional 75,569 shares during the period. Regeneron Pharmaceuticals accounts for about 3.0% of Icon Wealth Advisors LLC's holdings, making the stock its 5th biggest holding. Icon Wealth Advisors LLC owned approximately 0.07% of Regeneron Pharmaceuticals worth $79,874,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of REGN. Rakuten Securities Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 19 shares during the last quarter. Stephens Consulting LLC purchased a new position in Regeneron Pharmaceuticals during the second quarter worth about $26,000. Sachetta LLC increased its position in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 10 shares during the last quarter. Crewe Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $28,000. Finally, Lynx Investment Advisory acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $33,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Down 0.9 %

REGN stock traded down $6.50 during trading on Friday, hitting $738.00. 1,029,390 shares of the company's stock were exchanged, compared to its average volume of 539,322. The business has a 50-day moving average price of $953.38 and a two-hundred day moving average price of $1,028.16. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $81.10 billion, a price-to-earnings ratio of 18.45, a PEG ratio of 2.81 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 52-week low of $735.95 and a 52-week high of $1,211.20.

Insider Activity

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business's stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company's stock, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.48% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Piper Sandler dropped their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating for the company in a report on Friday, November 1st. Oppenheimer dropped their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating for the company in a research note on Wednesday, November 6th. Evercore ISI decreased their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating on the stock in a research note on Thursday, October 24th. Citigroup began coverage on Regeneron Pharmaceuticals in a report on Thursday, November 14th. They set a "neutral" rating and a $895.00 target price for the company. Finally, Cantor Fitzgerald reiterated a "neutral" rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $1,099.55.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.